Sangamo Therapeutics, Inc. focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for Hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); preclinical programs in other LSDs; and research stage programs in central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and Shire International GmbH to develop preclinical development program in Huntington's disease, as well as license agreements with Sigma-Aldrich Corporation to develop laboratory research reagents and Dow AgroSciences, LLC to modify the protein expression of plant cells and plants. The company also has a research collaboration and license agreement with Pfizer Inc; and collaboration with Kite for developing ex vivo cell therapies in oncology. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGMO
Previous Symbol
CUSIP80067710
Phone510-970-6000
Debt
Debt-to-Equity Ratio0.07
Current Ratio6.32
Quick Ratio6.32
Price-To-Earnings
Trailing P/E Ratio-16.01
Forward P/E Ratio-15.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.57 million
Price / Sales31.29
Cash FlowN/A
Price / CashN/A
Book Value$3.72 per share
Price / Book3.01
Profitability
EPS (Most Recent Fiscal Year)($0.70)
Net Income$-54,560,000.00
Net Margins-88.78%
Return on Equity-22.06%
Return on Assets-13.93%
Miscellaneous
Employees182
Outstanding Shares102,090,000
Market Cap$1.10 billion
OptionableOptionable
Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions
What is Sangamo Therapeutics' stock symbol?
Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."
How were Sangamo Therapeutics' earnings last quarter?
Sangamo Therapeutics Inc (NASDAQ:SGMO) issued its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.02. The biopharmaceutical company had revenue of $23.56 million for the quarter, compared to analyst estimates of $26.96 million. Sangamo Therapeutics had a negative net margin of 88.78% and a negative return on equity of 22.06%. The company's quarterly revenue was up 99.5% compared to the same quarter last year. During the same period last year, the company posted ($0.15) earnings per share. View Sangamo Therapeutics' Earnings History.
When is Sangamo Therapeutics' next earnings date?
What price target have analysts set for SGMO?
8 Wall Street analysts have issued 12 month target prices for Sangamo Therapeutics' shares. Their predictions range from $10.00 to $30.00. On average, they expect Sangamo Therapeutics' share price to reach $19.6667 in the next twelve months. This suggests a possible upside of 75.4% from the stock's current price. View Analyst Price Targets for Sangamo Therapeutics.
What is the consensus analysts' recommendation for Sangamo Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sangamo Therapeutics.
What are Wall Street analysts saying about Sangamo Therapeutics stock?
Here are some recent quotes from research analysts about Sangamo Therapeutics stock:
- 1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (10/10/2018)
- 2. Wedbush analysts commented, "Neurocrine and collaborator Abbvie announced approval of Orilissa (elagolix) for the management of moderate to severe pain associated with Endometriosis. Abbvie is guiding for the drug to be available in early August. According to Neurocrine mgmt, WAC price is $844.87/ mo for both 150mg QD regimen and 200mg BID regimen. Max treatment duration is 24mo for former and 6mo for latter. We are not making any material changes to our Orilissa sales ests. Neurocrine is entitled to a $40M approval milestone payment in 3Q18 and tiered royalties, which we believe range from 16-20%. Reiterate BUY." (7/24/2018)
Has Sangamo Therapeutics been receiving favorable news coverage?
News articles about SGMO stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sangamo Therapeutics earned a news impact score of 0.9 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Sangamo Therapeutics' key competitors?
Some companies that are related to Sangamo Therapeutics include Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Regenxbio (RGNX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Spark Therapeutics (ONCE), Atara Biotherapeutics (ATRA), Autolus Therapeutics (AUTL) and Rubius Therapeutics (RUBY).
Who are Sangamo Therapeutics' key executives?
Sangamo Therapeutics' management team includes the folowing people:
- Dr. Alexander D. Macrae, CEO, Pres & Director (Age 55)
- Ms. Kathy Y. Yi, Sr. VP & CFO (Age 46)
- Dr. Edward R. Conner, Sr. VP & Chief Medical Officer (Age 45)
- Dr. Edward Rebar, Sr. VP & CTO
- Mr. McDavid Stilwell, VP of Corp. Communications & Investor Relations
Who are Sangamo Therapeutics' major shareholders?
Sangamo Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.19%), Wasatch Advisors Inc. (4.47%), FMR LLC (2.61%), Credit Suisse AG (2.15%), Teachers Advisors LLC (0.98%) and Wells Fargo & Company MN (0.88%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, H Stewart Parker, Kathy Yi, Saira Ramasastry, Steven J Mento and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.
Which major investors are selling Sangamo Therapeutics stock?
SGMO stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, FMR LLC, First Trust Advisors LP, Royce & Associates LP, American Century Companies Inc., Virtus ETF Advisers LLC, Frontier Capital Management Co. LLC and Opaleye Management Inc.. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Curt A Herberts III, Edward R Conner, Kathy Yi, Saira Ramasastry and Steven J Mento. View Insider Buying and Selling for Sangamo Therapeutics.
Which major investors are buying Sangamo Therapeutics stock?
SGMO stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Credit Suisse AG, Tocqueville Asset Management L.P., Capital Fund Management S.A., BlackRock Inc., Dimensional Fund Advisors LP, Handelsbanken Fonder AB and Nordea Investment Management AB. View Insider Buying and Selling for Sangamo Therapeutics.
How do I buy shares of Sangamo Therapeutics?
Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sangamo Therapeutics' stock price today?
One share of SGMO stock can currently be purchased for approximately $11.21.
How big of a company is Sangamo Therapeutics?
Sangamo Therapeutics has a market capitalization of $1.10 billion and generates $36.57 million in revenue each year. The biopharmaceutical company earns $-54,560,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 182 workers across the globe.
What is Sangamo Therapeutics' official website?
How can I contact Sangamo Therapeutics?
Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]
MarketBeat Community Rating for Sangamo Therapeutics (NASDAQ SGMO)
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe SGMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
